Astrazeneca plc, of London, said the FDA approved its Bydureon (exenatide) Pen for the once-weekly treatment of adults with type II diabetes, as an adjunct to diet and exercise to improve glycemic control. The company plans to launch the product, the first approval for the pen worldwide, in the U.S. later this year.